- Conditions
- HIV Infection, LTBI
- Interventions
- Dolutegravir (DTG), Isoniazid (INH), Rifapentine (RPT), Antiretroviral Therapy (ART), Pyridoxine (Vitamin B6)
- Drug · Dietary Supplement
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- San Francisco, California • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–16
of 16
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Tuberculosis
- Interventions
- RPT + INH once weekly for 3 months given by DOT, Isoniazid (INH) daily for 9 months
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 2 Years and older
- Enrollment
- 8,053 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2013
- U.S. locations
- 21
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Diego, California + 17 more
- Conditions
- Tuberculosis
- Interventions
- Rifapentine, 25-desacetyl Rifapentine, Isoniazid
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Tuberculosis
- Interventions
- rifapentine, rifapentine and moxifloxacin, control
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 12 Years and older
- Enrollment
- 2,516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 5
- States / cities
- San Francisco, California • New York, New York • Fort Worth, Texas + 2 more
- Conditions
- Tuberculosis
- Interventions
- Rifapentine, Moxifloxacin, Rifampin, Isoniazid, Pyrazinamide, Ethambutol, Pyridoxine
- Drug · Dietary Supplement
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 2,516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Pulmonary Tuberculosis
- Interventions
- Rifapentine, Isoniazid
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Tuberculosis
- Interventions
- Isoniazid, Rifapentine
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 2 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more
- Conditions
- Latent Tuberculosis Infection
- Interventions
- Self Administered Therapy (SAT), SMS reminders, isoniazid and rifapentine
- Behavioral · Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,002 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 9
- States / cities
- San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use, Drug Interaction Potentiation
- Interventions
- Doravirine (DOR), Rifapentine (RPT), Isoniazid (INH)
- Drug
- Lead sponsor
- Walter K. Kraft
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Osteomyelitis
- Interventions
- oral antibiotics, intravenous antibiotics
- Drug · Procedure
- Lead sponsor
- Julio Ramirez
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Healthy Volunteers
- Interventions
- Tenofovir alafenamide, Rifapentine, Isoniazid (INH), Pyridoxine
- Drug · Dietary Supplement
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Latent Tuberculosis
- Interventions
- Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks, Rifampin daily for 16 weeks
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- Not listed
- Enrollment
- 3,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Washington D.C., District of Columbia • Manhattan, New York + 3 more
- Conditions
- HIV Infected Population With Latent Tuberculosis
- Interventions
- rifapentene (RPT), darunavir/cobicistat (DRV/c), Isoniazid (INH), Pyridoxine
- Drug · Dietary Supplement
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Tuberculosis, HIV Infections
- Interventions
- Rifapentine (RPT), Isoniazid (INH), Pyridoxine (Vitamin B6)
- Drug · Dietary Supplement
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 21
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 17 more
- Conditions
- Latent Tuberculosis, End Stage Renal Disease, Renal Transplant Candidate for Right Kidney, Renal Transplant Candidate for Left Kidney
- Interventions
- 1 month Rifapentine, Isoniazid and Vitamin B6
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Tuberculosis, Latent Tuberculosis Infection
- Interventions
- Video Directly Observed Therapy, In-Person DOT
- Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- San Diego, California